Targeting Molecular Pathways with Camptothecin as Novel Therapy for Gastric Cancer

Journal of Gastrointestinal Surgery

Volumn 3, Issue 6, 1999, Pages 618-624

  Litvak, David A ^a   Papaconstantinou, Harry T ^a   Evers, B Mark ^a   Townsend Jr , Courtney M ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Apoptosis; Bcl 2; Camptothecin; Cell cycle; Gastric cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; PROTEIN BCL 2;

ADENOCARCINOMA; ANIMAL; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; DRUG EFFECT; HUMAN; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; STOMACH TUMOR; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033220246     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(99)80084-5     Document Type: Article

References (31)

1. Alexander HR, Kelsen DG, Tepper JC. Cancer of the stomach. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practices of Oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997, pp 1021-1054.
2. Breaux JR, Bringaze W, Chappuis C, Cohn I Jr. Adenocarcinoma of the stomach: A review of 35 years and 1710 cases. World J Surg 1990;14:580-586.
3. Slichenmyer WJ, Rowinsky EK, Donchower RC, Kauffman SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-291.
4. Aller P, Rius C, Mata F, Zorilla A, Cabanas C, Bellon T, Bernabeu C. Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemic cells. Cancer Res 1992;52:1245-1251.
5. Khaoustov VT, Ozer A, Smith JR, Noda A, Mearns M, Krishnan B, Slagle BL, Yoffe B. Induction of senescent cell-derived inhibitor of DNA synthesis gene, SDI1, in hepatoblastoma (HepG2) cells arrested in the G2-phase of the cell cycle by 9-nitrocamptothecin. Lab Invest 1995;73:118-127.
6. Traganos F, Seiter K, Feldman E, Halicka HD, Darzynkiewicz. Z. Induction of apoptosis by camptothecin and topotecan. Ann N Y Acad Sci 1996;803:101-110.
7. Nagai S, Yamauchi M, Satta T, Kodera Y, Kondou K, Akiyaya S, Ito K, Takagi H. Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16. J Surg Oncol 1993;54:211-215.
8. Taguchi T, Wakui A, Hasegawa K, Niitani H, Furue H, Ohta K, Hattori T. Phase I clinical study of CPT-11. Jpn J Cancer Chemother 1990;17:115-120.
9. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E. Inhibition of cyclin-dependent kinases by p21. Mol Cell Biol 1995;6:387-400.
10. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994;9:3389-3396.
11. Litvak DA, Evers BM, Hwang KO, Hellmich MR, Ko TC, Townsend CM Jr. Butyrate-induced differentiation of Caco-2 cells is associated with apoptosis and early induction of p21waf1/cip1 and p27kipl. Surgery 1998;124:161-170.
12. Yoshida K, Murohashi I, Hirashima K. p53-independent induction of p21 (WAF1/CIP1) during differentiation of HL-60 cells by tumor necrosis factor alpha. Int J Hematol 1996;65:41-48.
13. Hetts SW. To die or not to die: An overview of apoptosis and its role in disease. JAMA 1998;279:300-307.
14. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Sairo D, Hasebe T, Mukai K, Seki S, Sairo H, Johnston PG. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998;4:1469-1474.
15. Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997;79:2067-2072.
16. Ogawa M, Maeda K, Onoda N, Chung YS, Sowa M. Loss of p21 WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer 1997;75:1617-1620.
17. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N, Expression of p53 and p51 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Dis Sci 1998;43:964-970.
18. Ikeguchi M, Saito H, Katano K., Gomyo Y, Tsujitani S, Maeta M, Kaibara N. Relationship between the long-term effects of intraperitoneal chemotherapy and the expression of p53 and p21 in patients with gastric carcinoma at stage IIIa and stage IIIb. Int Surg 1997;82:170-174.
19. Inada T, Kikuyama S, Ichikawa A, Igarashi S, Ogata Y. Bcl-2 expression as a prognostic factor of survival of gastric carcinoma. Anticancer Res 1998;18:2003-2010.
20. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H, Johnston PG, Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998;4:1469-1474.
21. Committee on Care and Use of the "Nude" Mouse. Guide for the care and use of the nude (thymus-deficient) mouse in biomedical research. ILAR News 1976;19:M1-M20.
22. Litvak DA, Papaconstantinou HT, Hwang KO, Kim M, Evers BM, Townsend CM Jr. Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways. Surgery 1999;126:223-230.
23. Liu W, Zhang R. Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol 1998; 12:793-804.
24. Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J, Groscurth P. Topoisomerase-I inhibitors for human glioma: Differential modulation of p53, p21, bax, and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β-lapachone. Int J Cancer 1997;73:707-714.
25. Akama Y, Yasui W, Kuniyasu H, Yokozaki H, Akagi M, Tahara H, Ishikawa T, Tahara E. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines. Jpn J Cancer Res 1996;87:824-830.
26. Cho JH, Kim WH. Altered topographic expression of p21WAF1/CIP1/SDI1, bcl2 and P53 during gastric carcinogenesis. Pathol Res Pract 1998;194:309-317.
27. Ikeguchi M, Tatebe S, Kaibara N, Ito H. Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis. Eur Surg Res 1997;29:396-402.
28. Inada T, Ichikawa A, Igarashi S, Kubota T, Ogata Y. Effect of preoperative 5-fluorouracil on apoptosis of advanced gastric cancer. J Surg Oncol 1997;65:106-110.
29. Clarke MR, Safatle-Ribeiro AV, Ribeiro U, Sakai P, Reynolds JC. bcl-2 protein expression in gastric remnant mucosa and gastric cancer 15 or more years after partial gastrectomy. Mod Pathol 1997;10:1021-1027.
30. Jang SJ, Ahn MJ, Paik SS, Kong G, Keum JS, Park YW, Lee JD. Expression of cyclin dependent kinase inhibitor p21 WAF1 alone and in combination with p27KIP1 shows prognostic value in gastric carcinoma. J Korean Med Sci 1998;13:369-376.
31. Nakata B, Chung KH, Ogawa M, Ogawa Y, Yanagawa K, Muguruma K, Inoue T, Yamashita Y, Onoda N, Macda K, Sawada T, Sowa M. p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today 1998;28:595-598.